
Private psychedelics medicine company Beckley Psytech Ltd. has acquired 100% of clinical-stage life sciences company Eleusis Therapeutics Ltd., entitling the former to full developmental and commercial rights of the latter’s assets.
Eleusis CEO Shlomi Raz will become Beckley’s CBO, while the Eleusis research and development team will be immediately integrated into the company.